Zura Bio set to showcase at the Jefferies Global Healthcare Conference
Zura Bio, a clinical-stage immunology company, is making strides in the development of novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company's key pipeline candidates include the lead product, tibulizumab (ZB-106), and other product candidates such as crebankitug (ZB-168) and torudokimab (ZB-880).
Tibulizumab (ZB-106) is currently under evaluation in two separate Phase 2 clinical studies. One study, TibuSURE, is focused on systemic sclerosis, a chronic connective tissue disorder, while the other, TibuSHIELD, targets hidradenitis suppurativa, a chronic skin condition.
Crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being further evaluated for their potential across a broad range of autoimmune and inflammatory conditions.
Zura Bio's senior leadership team will present a corporate overview at the Jefferies Global Healthcare Conference on June 4, 2025. The live webcast of the presentation will be available on the News & Events page in the Investors section of the Zura Bio website. A replay of the presentation will be accessible following the event and will remain archived on the website for at least 30 days.
For more information about Zura Bio Limited, please visit their website at www.zurabio.com or email [email protected]. Megan K. Weinshank serves as the Head of Corporate Affairs at Zura Bio Limited.
Zura Bio is a clinical-stage, multi-asset immunology company dedicated to developing innovative treatments for autoimmune and inflammatory diseases. The company's mission is to improve the lives of patients with high medical need by advancing its pipeline of novel dual-pathway antibodies.
News about Zura Bio's advancements in the medical-conditions sector, particularly autoimmune and inflammatory diseases, are circulating. Their lead product, tibulizumab (ZB-106), is being evaluated in phase 2 clinical studies for systemic sclerosis and hidradenitis suppurativa, while crebankitug (ZB-168) and torudokimab (ZB-880) are being further explored for their potential in various health-and-wellness areas, such as therapies-and-treatments for other autoimmune and inflammatory conditions. Zura Bio will present a corporate overview at the Jefferies Global Healthcare Conference on June 4, 2025, which will be accessible via live webcast and replay on their website for 30 days.
